All In Biotech

Drug Trial Radar · NCT06660069

A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

A 12-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Nov 18, 2024

Primary completion

Mar 11, 2025

Study completion Mar 11, 2025

Sponsor

Lead sponsor
HALEONIndustry
Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the ability of a marketed Cetylpyridinium Chloride (CPC) mouthwash alongside a marketed Stannous Fluoride (SnF2) toothpaste in improving gingival health and reducing plaque accumulation, compared to the use of a regular fluoride toothpaste alone in participants with clinically measurable plaque-induced gingivitis.

Conditions

  • Dental Plaque
  • Gingivitis

Interventions

  • Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)Drug

    Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.

  • CPC Mouthwash (Parodontax Active Gum Health Mouthwash)Drug

    Mouthwash containing 0.07% w/w CPC.

  • Regular Fluoride Toothpaste (Crest Cavity Protection)Drug

    Toothpaste containing 0.243% w/w sodium fluoride.

  • Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)Drug

    Toothpaste containing 0.454% w/w SnF2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Salus Research

    Fort Wayne, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.